Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity Publisher



Roohipoor R¹ ; Karkhaneh R¹ ; Riaziesfahani M^{1, 2} ; Dastjani Farahani A¹ ; Khodabandeh A¹ ; Ebrahimi Adib N¹ ; Imani M¹ ; Khojasteh Jafari H¹ ; Riaziesfahani H¹ ; Hosseinpour J¹ ; Zarei M¹ ; Ghasemi H¹ ; Mirghorbani M¹ ; Yaseri M¹ Show All Authors Show Affiliations
Source: Ophthalmology Retina Published:2018

Abstract

Purpose: To compare the outcomes of patients with type I retinopathy of prematurity (ROP) treated with either intravitreal bevacizumab (IVB) or retinal laser photocoagulation (RLP). Design: Retrospective case series. Participants: Infants treated for type I ROP with IVB or RLP. Methods: Patients who were born between January 2011 and December 2014 and were treated in Farabi Eye Hospital were included. The outcomes were stratified and analyzed, based on the treatment type and ROP zone. Main Outcome Measures: Need for retreatment, time to regression, refractive errors, retinal adverse anatomic outcomes, and rate of complications. Results: Five hundred twenty-three patients were treated for type 1 ROP, of whom 493 (986 eyes) met inclusion criteria. Seven hundred twenty-four eyes (73.4%) received IVB, and 262 eyes (26.5%) received RLP. Re-treatment (because of recurrent or persistent retinopathy) occurred in 14.4% (106/724) of eyes initially treated with IVB and in 8.8% (23/262) eyes initially treated with RLP (P = 0.065). Re-treatment was not significantly different between the 2 groups for patients with zone I disease (P = 0.978). Re-treatment rate was considerably higher in patients with zone II disease treated with IVB (69/558 [12.3%]) compared with those treated with RLP (20/251 [7.9%]; P = 0.017). In the IVB group, 82.8% and 53.4% of eyes showed an avascular area in zone III (despite ROP regression) at 1 and 2 years after treatment, respectively. The spherical power and the spherical equivalent were significantly higher in eyes treated with RLP (−1.31±2.83 diopters [D] and −2.84±2.77 D, respectively) than eyes treated with IVB (0.19±3.21 D and −1.26±3.19 D, respectively; P = 0.016 and P = 0.007, respectively). Differences in astigmatic power were not significant. Conclusions: Both IVB and RLP are effective treatments for type 1 ROP. Longer follow-up time is necessary for infants treated with IVB. More patients with zone II disease treated with RLP achieved disease regression after a single treatment than those who received IVB, although outcomes after re-treatment were comparable except for a greater refractive error in patients treated with RLP. © 2018 American Academy of Ophthalmology